These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 33358235)

  • 1. Impact of bone mineral density in reducing fracture risk in patients receiving alendronate plus alfacalcidol therapy.
    Itoi E; Uemura Y; Ohta H; Nakamura T; Fukunaga M; Orimo H; Shiraki M
    J Orthop Sci; 2021 Nov; 26(6):1085-1093. PubMed ID: 33358235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Superiority of a combined treatment of Alendronate and Alfacalcidol compared to the combination of Alendronate and plain vitamin D or Alfacalcidol alone in established postmenopausal or male osteoporosis (AAC-Trial).
    Ringe JD; Farahmand P; Schacht E; Rozehnal A
    Rheumatol Int; 2007 Mar; 27(5):425-34. PubMed ID: 17216477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differences of therapeutic effects on regional bone mineral density and markers of bone mineral metabolism between alendronate and alfacalcidol in Japanese osteoporotic women.
    Takata S; Abbaspour A; Yonezu H; Yasui N
    J Med Invest; 2007 Feb; 54(1-2):35-40. PubMed ID: 17380012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the effects of alendronate and alfacalcidol on hip bone mineral density and bone turnover in Japanese men having osteoporosis or osteopenia with clinical risk factors for fractures.
    Iwamoto J; Sato Y; Uzawa M; Takeda T; Matsumoto H
    Yonsei Med J; 2009 Aug; 50(4):474-81. PubMed ID: 19718394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of alendronate plus alfacalcidol in osteoporosis patients with a high risk of fracture: the Japanese Osteoporosis Intervention Trial (JOINT) - 02.
    Orimo H; Nakamura T; Fukunaga M; Ohta H; Hosoi T; Uemura Y; Kuroda T; Miyakawa N; Ohashi Y; Shiraki M;
    Curr Med Res Opin; 2011 Jun; 27(6):1273-84. PubMed ID: 21554143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential of alfacalcidol for reducing increased risk of falls and fractures.
    Ringe JD; Schacht E
    Rheumatol Int; 2009 Aug; 29(10):1177-85. PubMed ID: 19159932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention of glucocorticoid induced osteoporosis with alendronate or alfacalcidol: relations of change in bone mineral density, bone markers, and calcium homeostasis.
    Jacobs JW; de Nijs RN; Lems WF; Geusens PP; Laan RF; Huisman AM; Algra A; Buskens E; Hofbauer LC; Oostveen AC; Bruyn GA; Dijkmans BA; Bijlsma JW
    J Rheumatol; 2007 May; 34(5):1051-7. PubMed ID: 17407214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.
    Gallagher JC; Rosen CJ; Chen P; Misurski DA; Marcus R
    Bone; 2006 Dec; 39(6):1268-75. PubMed ID: 16884968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis.
    de Nijs RN; Jacobs JW; Lems WF; Laan RF; Algra A; Huisman AM; Buskens E; de Laet CE; Oostveen AC; Geusens PP; Bruyn GA; Dijkmans BA; Bijlsma JW;
    N Engl J Med; 2006 Aug; 355(7):675-84. PubMed ID: 16914703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Additive impact of alfacalcidol on bone mineral density and bone strength in alendronate treated postmenopausal women with reduced bone mass.
    Felsenberg D; Bock O; Börst H; Armbrecht G; Beller G; Degner C; Stephan-Oelkers M; Schacht E; Mazor Z; Hashimoto J; Roth HJ; Martus P; Runge M
    J Musculoskelet Neuronal Interact; 2011 Mar; 11(1):34-45. PubMed ID: 21364273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of alendronate and alfacalcidol on bone in patients with myasthenia gravis initiating glucocorticoids treatment.
    Lv F; Guan Y; Ma D; Xu X; Song Y; Li L; Jiang Y; Wang O; Xia W; Xing X; Li M
    Clin Endocrinol (Oxf); 2018 Mar; 88(3):380-387. PubMed ID: 29266368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alendronate protects premenopausal women from bone loss and fracture associated with high-dose glucocorticoid therapy.
    Okada Y; Nawata M; Nakayamada S; Saito K; Tanaka Y
    J Rheumatol; 2008 Nov; 35(11):2249-54. PubMed ID: 19031508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alendronate reduced vertebral fracture risk in postmenopausal Japanese women with osteoporosis: a 3-year follow-up study.
    Kushida K; Shiraki M; Nakamura T; Kishimoto H; Morii H; Yamamoto K; Kaneda K; Fukunaga M; Inoue T; Nakashima M; Orimo H
    J Bone Miner Metab; 2004; 22(5):462-8. PubMed ID: 15316867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Minodronate combined with alfacalcidol versus alfacalcidol alone for glucocorticoid-induced osteoporosis: a multicenter, randomized, comparative study.
    Soen S; Yamamoto K; Takeuchi T; Tanaka Y; Tanaka S; Ito M; Nakano T; Hagino H; Hirakawa A; Matsumoto T
    J Bone Miner Metab; 2020 Jul; 38(4):511-521. PubMed ID: 31970477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Forearm bone mineral density and fracture incidence in postmenopausal women with osteoporosis: results from the ACTIVExtend phase 3 trial.
    Watts NB; Dore RK; Baim S; Mitlak B; Hattersley G; Wang Y; Rozental TD; LeBoff MS
    Osteoporos Int; 2021 Jan; 32(1):55-61. PubMed ID: 32935170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eldecalcitol is superior to alfacalcidol in maintaining bone mineral density in glucocorticoid-induced osteoporosis patients (e-GLORIA).
    Matsumoto T; Yamamoto K; Takeuchi T; Tanaka Y; Tanaka S; Nakano T; Ito M; Tomomitsu T; Hirakawa A; Soen S
    J Bone Miner Metab; 2020 Jul; 38(4):522-532. PubMed ID: 32140784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Three-year experience with combined treatment with alendronate and alfacalcidol in Japanese patients with severe bone loss and osteoporotic fracture.
    Iwamoto J; Sato Y; Uzawa M; Takeda T; Matsumoto H
    Ther Clin Risk Manag; 2011; 7():257-64. PubMed ID: 21753888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of alendronate or alfacalcidol on bone metabolic indices and bone mineral density in patients with ophthalmologic disease treated with glucocorticoid.
    Ikeda T; Maruyama K; Kaji H; Akagi M
    Mod Rheumatol; 2014 Jul; 24(4):671-6. PubMed ID: 24313921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Importance of alfacalcidol in clinical conditions characterized by high rate of bone loss.
    Reginster JY; Lecart MP; Richy F
    J Rheumatol Suppl; 2005 Sep; 76():21-5. PubMed ID: 16142847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Additional beneficial effects of alendronate in growth hormone (GH)-deficient adults with osteoporosis receiving long-term recombinant human GH replacement therapy: a randomized controlled trial.
    Biermasz NR; Hamdy NA; Janssen YJ; Roelfsema F
    J Clin Endocrinol Metab; 2001 Jul; 86(7):3079-85. PubMed ID: 11443170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.